Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gentian Diagnostics ASOSTO:GENTOO 60 Return-on-Tangible-Asset is 7.87% as of Jun. 2026. GuruFocus rates OSTO:GENTOO with a GF Score™ of 60/100 and a GF Value™ of kr53.59 (Modestly Undervalued). Among 853 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 59.2% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Gentian Diagnostics AS's annualizedNet Income for the quarter that ended in Jun. 2026 was kr17.7 Mil. Gentian Diagnostics AS's average total tangible assets for the quarter that ended in Jun. 2026 was kr224.7 Mil. Therefore, Gentian Diagnostics AS's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 7.87%.
The historical rank and industry rank for Gentian Diagnostics AS's Return-on-Tangible-Asset or its related term are showing as below:
OSTO:GENTOo'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -17.97 Med: -9.93 Max: 25.09
Current: -3.92
During the past 13 years, Gentian Diagnostics AS's highest Return-on-Tangible-Asset was 25.09%. The lowest was -17.97%. And the median was -9.93%.
OSTO:GENTOo's Return-on-Tangible-Asset is ranked worse than 59.2% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.76
vs OSTO:GENTOo: -3.92
Gentian Diagnostics AS (OSTO:GENTOo) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Gentian Diagnostics AS Return-on-Tangible-Asset Related Terms
Gentian Diagnostics AS Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS Return-on-Tangible-Asset Chart
OSTO:GENTOO vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.87% mean?
Gentian Diagnostics AS (OSTO:GENTOO) has a Return-on-Tangible-Asset of 7.87% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #505 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 59.2%.
Is Gentian Diagnostics AS's Return-on-Tangible-Asset too high?
Gentian Diagnostics AS's current Return-on-Tangible-Asset is 7.87%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.76. Gentian Diagnostics AS's value of 7.87% is 935.5% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #505 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #505 out of 853 companies for Return-on-Tangible-Asset. This places Gentian Diagnostics AS in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.76. Gentian Diagnostics AS's value of 7.87% is 935.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.76, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Return-on-Tangible-Asset of 7.87% is 935.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Return-on-Tangible-Asset is 7.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSTO:GENTOO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr53.59, compared to a current price of kr40.00 — trading 25.4% below its estimated fair value. The current Return-on-Tangible-Asset is 7.87% and 935.5% above the Medical Devices & Instruments industry median of 0.76. Gentian Diagnostics AS's overall GF Score™ is 60/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Gentian Diagnostics AS (OSTO:GENTOO), the current Return-on-Tangible-Asset is 7.87% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSTO:GENTOO) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr40.00 is trading 25.4% below its estimated GF Value™ of kr53.59.
GuruFocus considers Gentian Diagnostics AS to be Modestly Undervalued.
Key valuation signals for OSTO:GENTOO:
Return-on-Tangible-Asset: 7.87%
GF Value™: kr53.59 vs. price of kr40.00 (25.4% below fair value)
Industry Position: 935.5% above the Medical Devices & Instruments median (#505 of 853)
No single metric tells the full story. See the OSTO:GENTOO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
60GF Score
Get the complete analysis for OSTO:GENTOO
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GENTOO has been successfully added to your 
